(Q34810763)

4 August 2017

1 reference

title

The pemetrexed/gemcitabine combination in pancreatic cancer (English)

1 reference

4 August 2017

1 reference

Hedy Lee Kindler

1

1 reference

PubMed ID

12209673

4 August 2017

language of work or name

English

0 references

publication date

1 August 2002

1 reference

4 August 2017

1 reference

4 August 2017

95

1 reference

4 August 2017

928-932

1 reference

4 August 2017

4 Suppl

1 reference

4 August 2017

Cancer statistics, 2001

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10755

Gemcitabine: progress in the treatment of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10755

Phase II trial of gemcitabine (2,2'-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10755

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10755

A dideazatetrahydrofolate analogue lacking a chiral center at C-6, N-[4-[2-(2-amino-3,4-dihydro-4-oxo-7H-pyrrolo[2,3-d]pyrimidin-5- yl)ethyl]benzoyl]-L-glutamic acid, is an inhibitor of thymidylate synthase

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10755

Activity of the multitargeted antifolate LY231514 in the human tumor cloning assay.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10755

A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10755

Phase II study of the multitargeted antifolate LY231514 (ALIMTA, MTA, pemetrexed disodium) in patients with advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10755

Initial phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, using the modified continual reassessment method for dose escalation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10755

inferred from DOI database lookup

7 January 2021

based on heuristic

Phase I and pharmacologic study of sequences of gemcitabine and the multitargeted antifolate agent in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10755

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1002/CNCR.10755

1 reference

release_zzto25u4mzgixim56vr4lncv6y

4 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/zzto25u4mzgixim56vr4lncv6y

mapped directly with Wikidata item

24 November 2022

based on heuristic

PubMed ID

12209673

1 reference

PubMed ID

12209673